Financials

This section of the Anika Therapeutics, Inc. InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing. 

Please note:  All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes.  COMPANY NAME assumes no responsibility for the accuracy of this data and provides it for informational purposes only.

NASDAQANIK
Beta0.83
Shares Outstanding14.8M
Average Volume (10 days)70.2K
Qtrly Dividend (Ann. Yield)-- (--)

Per Share Data

Earnings (TTM)($5.25)
Sales (TTM)$2.90
Book Value (MRQ)$14.06
Cash Flow (TTM)$0.11
Cash (MRQ)$7.43

Analyst Views

Current Mean RecommendationBuy
Strong Buy1
 
Buy0
 
Hold1
 
Underperform0
 
Sell0
 

Recent Insider Transactions

Griffin Stephen
EVP, CFO and Treasurer
38,520
Acquire
Jun 3, 2024
Jellison William
468
Acquire
Jun 3, 2024
Capper Joseph H.
468
Acquire
Jun 3, 2024
Griffin Stephen
EVP, CFO and Treasurer
96,525
Acquire
Jun 3, 2024
Anne Nunes
SVP, Chief Operations Officer
26,442
Acquire
Mar 15, 2024

Recent SEC Filings

DEFA14A
DEFA14A
Jun 25, 2024
DEF 14A
Proxy Statement
Jun 11, 2024
ARS
Annual Report
Jun 11, 2024
3
New Insider
Jun 5, 2024
3
New Insider
Jun 5, 2024
Currency in USD.
Quote data delayed by at least 15 minutes.
Earnings and Analyst data provided by Zacks.
Insiders data provided by Morningstar.
To Top